PDB17 Comparison of Clinical and Economic Outcomes Associated With Dpp4 Inhibitors (DPP4I) Versus Sulfonylurea (SU) in Combination with Metformin (MET) or Pioglitazone (PIO) for the Treatment of Type 2 Diabetes Mellitus (T2DM)
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.348
https://www.valueinhealthjournal.com/article/S1098-3015(12)02061-X/fulltext
Title :
PDB17 Comparison of Clinical and Economic Outcomes Associated With Dpp4 Inhibitors (DPP4I) Versus Sulfonylurea (SU) in Combination with Metformin (MET) or Pioglitazone (PIO) for the Treatment of Type 2 Diabetes Mellitus (T2DM)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02061-X&doi=10.1016/j.jval.2012.08.348
First page :
A661
Section Title :
Diabetes/Endocrine Disorders
Open access? :
No
Section Order :
1887